Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19-65
SponsorKeimyung University Dongsan Medical Center
About this trial
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.
Eligibility criteria
Qualifiers
Age 19 - 65
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma,
peripheral T-cell lymphoma, NOS
Disqualifiers
Adult T cell leukemia/lymphoma, Lymphoblastic lymphoma, Primary cutaneous CD30+ T cell disorders Mycosis fungoides, Sezary SD
Patients who have previously performed Allo-HSCT
T cell lymphoma with primary central nervous system (CNS) Involvement.
Patients with a known history of HIV seropositivity or HCV (+).
Trial design
Treatments tested in this trial
- Busulfan
- Fludarabine
Treatment groups
34 Participants
are divided into 1 treatment groupSponsors and collaborators
Keimyung University Dongsan Medical Center
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Collaborator
Source ClinicalTrials.gov